Pre-Clinical Pipeline
Next Generation α7 nicotinic acetylcholine receptor NAM Program
Utilizing our expertise in ion channel biology and translational medicine we developed next generation patented orally bioavailable small molecule series of NAM targeting α7 nicotinic acetylcholine receptor that can be potentially positioned for the treatment of CNS disorders of high unmet clinical need.
Kv3.1/3.2 Program
Bionomics’ molecules target Kv3.1/3.2 ion channels on Parvalbumin (+), GABAergic interneurons in the pre-frontal cortex. These small molecule Kv3.1 / Kv3.2 potassium ion channels activators have potential for improving cognitive dysfunction and negative symptoms in schizophrenia and other illnesses such as Autism Spectrum Disorder and Alzheimer’s Disease.
Representative molecules from each series have been associated with the reversal of pharmacologically induced cognitive deficits in mouse and rat models at a rate equivalent to risperidone, an antipsychotic drug used to treat schizophrenia, used as the positive control.
Pan Nav Program
Gain & Loss-of-function mutations in Nav1.7, 1.8 and 1.9 are associated with human pain syndromes where extreme pain or no pain is experienced. Therefore Pan Nav (1.7/1.8/1.9) inhibitors may be a potential treatment for chronic pain and other potentially large unmet medical needs.
Bionomic’ Pan Nav inhibitors were selected out of more than 1000 synthesized compounds, with 2 patents filed for the lead and backup compounds. These small molecules have functional selectivity for voltage gated sodium channels: Nav1.7, Nav1.8 and potentially Nav1.9.
Representative molecules from each series have been observed to reverse pain in the formalin paw model in mice.
For any partnering enquiries, please contact us here